• In cellulo screening of 30,000-compound libraries using replicative viruses
• Viability assays based on inhibition of virus-induced cytopathic effects (MTS assay)
• Rapid, cost-effective primary screening campaigns
• Phenotypic antiviral screening using various human pathogenic viruses

• Viral replication assays by quantitative RT-PCR
• Characterization against multiple viral families and genotypes
• Determination of EC₅₀ and EC₉₀ values per FDA quality standards
• In-cellulo cytotoxicity profiling using fluorescent viability markers (e.g., resazurin)

Available viral families and strains:

• Flaviviruses: Dengue (25+ strains), Yellow Fever, Zika, WNV, JEV, TBEV
• Alphaviruses: Chikungunya, VEEV, Old and New World lineages
• Bunyavirales: RVFV, Toscana virus, nairoviruses, orthobunyaviruses

In vivo validation:

• BSL-3+ animal facility with iso-cage housing (HEPA-filtered)
• Validated models for flavivirus-induced hemorrhagic and neurological disease
• Quantification of viral load in tissues (brain, liver, spleen, blood)

• Industry partnerships for hit validation on dengue virus panels (10+ clinical isolates)
• Phylogenetic selection of strains and synthetic reconstruction for gaps
• Preclinical development of antiviral candidates submitted to regulatory agencies (e.g., FDA)